Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.

Biotechnology

Accession Therapeutics Limited

Bent Jakobsen

Stephanie Smith Bewick

Tony Hinton

Rita Figueiredo

Lok Hang Mak

Johanne Pentier, Ph. D.

Jez (Andrew) Gerry

Andy Johnson

Alan Parker

The Clinical and Quality Operations team at Accession Therapeutics Limited is responsible for overseeing the planning, execution, and management of clinical trials to ensure the safe and effective development of the Trocept platform. This team ensures compliance with regulatory standards, implements quality assurance protocols, and collaborates across functions to streamline translational sciences and CMC (Chemistry, Manufacturing, and Controls) processes. Their expertise is crucial in driving the advancement of innovative cancer therapies from preclinical stages to successful clinical evaluation.

Clinical and Quality Operations

Scientific Research Team

Leadership Team

Clinical and Quality Operations

About

Team members

Other teams at Accession Therapeutics Limited

Scientific Research Team

Leadership Team